Jain PharmaBiotech, Feb 2012, Pages: 639
Transcriptional targeting for cancer gene therapyTargeted epidermal growth factor-mediated DNA delivery
Gene-based targeteddrug delivery to tumors
Targeting gene expression to hypoxic tumor cells
Targeting
Jain PharmaBiotech, Feb 2012, Pages: 264
Combinations of statins with other drugs to increase efficacy
Controlled release fenofibrate
Extended release nicotinic acid
Intravenous infusion of lipoprotein preparations to raise HDL
Innovative approaches
Jain PharmaBiotech, Feb 2012, Pages: 345
in the area of targeted delivery by systemic administration.
Many of the new developments in the treatment of neurological disorders will be biological therapies and these will require innovative methods
Decision Resources, Inc., Dec 2009, Pages: 58
TargetedTherapies
France
Recent Developments in the General Reimbursement Environment
Flexible Funding Arrangements for InnovativeDrugs
Promoting Good Use of Cancer Therapies
New National Cancer
Jain PharmaBiotech, Feb 2012, Pages: 1008
Innovations in cell-based therapy of cancer
Use of immortalized cells
Cancer therapy based on natural killer cells
Mesothelin as a target for cancer immunotherapy
Nanomagnets for targeted cell-based cancer
Markets and Markets, Nov 2011, Pages: 286
.3.1.4 TargetedTherapy
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 InnovativeDrugs Driving The Market
4.2.2 Increase In Research & Development In Oncology Therapeutic Area
4.2.3 Developments
Global Industry Analysts, Inc., Oct 2011, Pages: 897
Propel Growth 23
Growth Restraints 23
High Prices of TargetedTherapies Act as a Speed Breaker 23
Table 6: Estimated Average Monthly Cost of Select Leading
Cancer Drugs in the US as of 2008 24
Limited
Cientifica Ltd., Feb 2012, Pages: 108
annual growth rate (CAGR)—53.8%—in the next decade.
Drugs are loaded into nanocarriers (also called nanoshells or nanoparticles, between 1 and 100 nm), then transported through the body to the target site
JZMed Inc., Oct 2009, Pages: 230
drug companies for a broad range of therapeutic targets. More significantly, driven by a number of positive factors, this sector of the Chinese pharmaceutical industry has gained an extraordinary growth
Cutting Edge Information, Feb 2009, Pages: 201
Which Alzheimer’s blockbuster faces diminishing sales within the next decade? What has the potential to take its place? Which class of MS drugs is emerging as successful? What innovative treatments
GBI Research, Feb 2011, Pages: 100
Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market
Summary
GBI Research, the leading business intelligence provider, has released its latest
Decision Resources, Inc., May 2010, Pages: 22
an attractive market for drug developers despite various obstacles that are challenging market growth.
Questions Answered in this Report:
- The antivirals market has grown steadily since 2004 and, excepting
GBI Research, Jan 2012, Pages: 87
analysis by GBI Research’s team of industry experts.
GBI Research analysis shows that the global market for immunosuppressant drugs used in transplants is projected to increase at a compound annual growth
Decision Resources, Inc., May 2009, Pages: 40
of Diabetes Drugs
- Lifestyle Drugs and Aging
- Multimorbidity
- Never Too Old
- Nothing Beats Innovation
- Nutrition
- Therapeutic Window
Outlook
Tables
1. Market-Leading Drugs and Promising Emerging
Business Insights, Nov 2006, Pages: 137
technologies are changing drug delivery and how these can be implemented into your R&D process. Assess the impact of innovation in therapy areas including oncology, diabetes and infectious diseases and identify
TriMark Publications, Jan 2011, Pages: 1679
, the science of individualizing drugtherapy based on the genetic makeup of individual patients, offers an unusual opportunity for future market growth. Applying pharmacogenomics would allow doctors to treat
Espicom Business Intelligence Ltd, March 2011, Pages: 52
at a time of challenge for the branded industry?
Orphan Drugs Snapshot:
In recent years, there has been a surge of interest in this area as, despite the increasing number of products, the unmet medical
Jain PharmaBiotech, Feb 2012, Pages: 534
transfer protein
Cholesterol 24S-hydroxylase as a drugtarget for AD
Selectively increase of ApoA-I production
Neurotrophic factors
Activity-dependent neuroprotective protein
Brain derived neurotrophic
Business Insights, July 2007, Pages: 128
innovatives in 2006, supplemented by novel chemotherapeutics, hormonals and targetedtherapies.
- Ten ‘blockbuster’ drugs are likely to emerge in cancer therapy over the next decade as recent and impending
